KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · IEX Real-Time Price · USD
14.55
+0.35 (2.46%)
At close: Jul 19, 2024, 12:00 AM
14.33
-0.22 (-1.51%)
Pre-market: Jul 22, 2024, 9:01 AM EDT
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 150 employees as of April 30, 2024. The number of employees increased by 32 or 27.12% compared to the previous year.
Employees
150
Change (1Y)
32
Growth (1Y)
27.12%
Revenue / Employee
n/a
Profits / Employee
-$844,293
Market Cap
621.80M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Pediatrix Medical Group | 5,450 |
PetIQ | 1,933 |
Ginkgo Bioworks Holdings | 1,218 |
REGENXBIO | 344 |
Entrada Therapeutics | 159 |
Astria Therapeutics | 59 |
Celcuity | 55 |
ArriVent BioPharma | 40 |
KALV News
- 11 days ago - KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results - Business Wire
- 20 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 25 days ago - KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11 - Business Wire
- 4 weeks ago - KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema - Business Wire
- 6 weeks ago - KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024 - Business Wire
- 7 weeks ago - KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 - Business Wire
- 7 weeks ago - KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema - Business Wire
- 2 months ago - KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024 - Business Wire